Humana Inc vs iShares MBS ETF — how do they compare? Humana Inc trades at $449.45 (market cap $46.49B), while iShares MBS ETF trades at $89.7 (market cap $35.41B). The key difference: Humana Inc is the larger of the two by market cap, and Humana Inc pays a 0.91% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and iShares MBS ETF for 96 Days on average.
| HUM | MBB | |
|---|---|---|
Market Cap | $46.49B | $35.41B |
Volume | 2,567,704 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $409.85 | $96.91 |
52-Week Low | $163.67 | $89.09 |
Typical Hold Time | 53 Days | 96 Days |
Enterprise Value | $53.84B | — |
Dividend Yield | 0.91% | — |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
MBB (iShares MBS ETF) trades at $89.22, down 0.16% amid bearish technical signals with 18 sell indicators versus 2 buy signals. The ETF faces pressure from rising intermediate-term rates and inflation concerns, with short interest surging 98.3% in September 2026 to 6.57 million shares. Recent institutional activity shows mixed sentiment with some firms increasing positions while technical indicators point to continued downward momentum.
The outlook remains challenging with convexity risk and borrower prepayment optionality limiting upside potential. Investment opportunity exists for income-focused investors through consistent dividend payments, but risks include duration exposure during potential rate hikes and persistent inflation pressures affecting mortgage-backed securities performance.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →